Skip to search formSkip to main contentSkip to account menu

Tafamidis meglumine

Known as: D-Glucitol, 1-Deoxy-1-(Methylamino)-, 2-(3,5-Dichlorophenyl)-6-Benzoxazolecarboxylate (1:1), D-Gluco-2,3,4,5,6-Pentahydroxy-N-Methylhexan-1-Aminium 2-(3,5-Dichlorophenyl)Benzoxazole-6-Carboxylate 
A soft gelatin capsule formulation containing the meglumine salt form of tafamidis, a small molecule and pharmacological chaperone with potential… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

Fx-1006A
TAFAMIDIS MEGLUMINE 20 mg ORAL CAPSULE [Vyndaqel]tafamidis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers
Tafamidis, a non‐nonsteroidal anti‐inflammatory benzoxazole derivative, acts as a transthyretin (TTR) stabilizer to slow… 
Review
2017
Review
2017
The endoplasmic reticulum: A hub of protein quality control in health and disease
Highly Cited
2016
Highly Cited
2016
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
Abstract Transthyretin hereditary amyloid polyneuropathy, also traditionally known as transthyretin familial amyloid… 
Review
2016
Review
2016
Current and future treatment of amyloid diseases
There are more than 30 human proteins whose aggregation appears to cause degenerative maladies referred to as amyloid diseases or… 
Highly Cited
2013
Highly Cited
2013
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial… 
Highly Cited
2013
Highly Cited
2013
Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, efficacy, and safety of tafamidis in… 
2013
2013
Tafamidis (Vyndaqel): A Light for FAP Patients
Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer… 
Highly Cited
2012
Highly Cited
2012
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
The transthyretin amyloidoses (ATTR) are invariably fatal diseases characterized by progressive neuropathy and/or cardiomyopathy… 
Review
2012
Review
2012
TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients
Familial amyloid polyneuropathy (FAP) is a rare condition caused by mutations of the transthyretin (TTR) gene and it is generally… 
Review
2011
Review
2011
Familial amyloid polyneuropathy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)